Acute @entity294 during adjuvant therapy for XXXX : a detailed analysis from a randomized intergroup trial.

@entity1 @entity137 @entity5 @entity294 @entity530 @entity1487
PURPOSE: During adjuvant radiotherapy (RT) for @entity5 , @entity1 receiving @entity1487 ( @entity1487 ) by protracted venous infusion have a higher risk of @entity294 than have @entity1 receiving bolus @entity1487 . @entity137 from a previously reported randomized clinical trial was analyzed to quantify the difference in this risk. Additionally, the persistence of @entity294 after RT was analyzed. METHODS AND MATERIALS: A total of 656 @entity1 were eligible. @entity1 with T3-4 N0-2 M0 or T1-2 N1-2 M0 resected, high-risk @entity5 were randomly allocated to receive @entity1487 by either protracted venous infusion or bolus during RT (50.4-54.0 Gy). Two cycles of bolus @entity1487 were given before and after RT. One-half of the first 445 @entity1 were also randomly allocated to receive lomustine in conjunction with the bolus @entity1487 . The incidence and severity of @entity294 in relation to @entity1 and treatment characteristics were evaluated. RESULTS: The rate of @entity294 was significantly greater in @entity1 receiving @entity1487 by protracted venous infusion than in @entity1 receiving bolus @entity1487 ; the difference was most pronounced for Grade 3 (severe) @entity294 (21% versus 13%, p = 0.007). The incidence and magnitude of @entity294 before and after RT were similar. @entity1 treated with an anterior resection had a higher rate of severe or life-threatening @entity294 than did @entity1 treated with an abdominoperineal resection (31% vs. 12%, p < 0.001). CONCLUSIONS: During @entity530 , @entity1 who receive @entity1487 by protracted venous infusion rather than by bolus have a higher risk of severe or life-threatening @entity294 during RT. This risk does not appear to persist during chemotherapy after completion of @entity530 .
